CRTX Share Price

Open 9.48 Change Price %
High 9.54 1 Day 0.01 0.11
Low 9.48 1 Week 0.00 0.00
Close 9.49 1 Month 0.00 0.00
Volume 163312 1 Year 0.00 0.00
52 Week High 12.53
52 Week Low 0.00
CRTX Important Levels
Resistance 2 9.55
Resistance 1 9.52
Pivot 9.50
Support 1 9.46
Support 2 9.43
NASDAQ USA Most Active Stocks
SIRI 4.30 -5.49%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
QQQ 115.67 0.17%
WRES 0.09 0.00%
More..
NASDAQ USA Top Gainers Stocks
QKLS 0.21 110.00%
LOCM 0.09 50.00%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PERF 1.90 22.58%
ASNA 7.01 20.24%
SBSA 4.60 17.95%
CEMP 7.55 15.27%
XXIA 15.55 14.76%
More..
NASDAQ USA Top Losers Stocks
PTIX 0.00 -100.00%
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OPXAW 0.01 -50.00%
VALV 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
More..

Cornerstone Therapeutics Inc. (NASDAQ: CRTX)

CRTX Technical Analysis 1.5
As on 3rd Feb 2014 CRTX Share Price closed @ 9.49 and we RECOMMEND Buy for LONG-TERM with Stoploss of 8.84 & Sell for SHORT-TERM with Stoploss of 9.52 we also expect STOCK to react on Following IMPORTANT LEVELS.
CRTX Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
CRTX Other Details
Segment EQ
Market Capital 127880384.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
CRTX Address
CRTX
N/A
CRTX Latest News
Interactive Technical Analysis Chart Cornerstone Therapeutics Inc. ( CRTX NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Cornerstone Therapeutics Inc.
CRTX Business Profile
Cornerstone Therapeutics Inc. is a specialty pharmaceutical company focused on commercializing products for the hospital, respiratory and related specialty markets. The Company�s promoted products include CUROSURF, ZYFLO CR, FACTIVE and SPECTRACEF. On December 30, 2011, the Company acquired Cardiokine, Inc., a specialty pharmaceutical company, focused on developing hospital products for cardiovascular indications. In March 2012, it acquired the North American product rights for FACTIVE (Gemifloxacin Mesylate) tablets. In June 2012, the Company acquired EKR Therapeutics, Inc. In February 2014, Chiesi Farmaceutici S.p.A acquired Cornerstone Therapeutics Inc.